APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Somatostatin Analogues (LA SSAs)

Compare research editions
View pricing & licenses

Selected research

Industry Research

Long-acting Somatostatin Analogues (LA SSAs) Industry Research Report 2026

28 December 2025116 pages

Choose your research edition.

Industry ResearchLong-acting Somatostatin Analogues (LA SSAs) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Somatostatin Analogues (LA SSAs) Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Long-acting Somatostatin Analogues (LA SSAs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Somatostatin Analogues (LA SSAs) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Somatostatin Analogues (LA SSAs) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Long-acting Somatostatin Analogues (LA SSAs) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Long-acting Somatostatin Analogues (LA SSAs) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Long-acting Somatostatin Analogues (LA SSAs) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Long-acting Somatostatin Analogues (LA SSAs) include Chiesi Farmaceutici S.p.A, Ipsen, Recordati Rare Diseases, Novartis and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Long-acting Somatostatin Analogues (LA SSAs) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Long-acting Somatostatin Analogues (LA SSAs) Market by Company

Chiesi Farmaceutici S.p.A

Ipsen

Recordati Rare Diseases

Novartis

Teva

Long-acting Somatostatin Analogues (LA SSAs) Segment by Type

Injections

Oral Capsules

Long-acting Somatostatin Analogues (LA SSAs) Segment by Application

Neuroendocrine Tumors

Acromegaly

Other

Long-acting Somatostatin Analogues (LA SSAs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Somatostatin Analogues (LA SSAs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Somatostatin Analogues (LA SSAs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Somatostatin Analogues (LA SSAs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Long-acting Somatostatin Analogues (LA SSAs) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Long-acting Somatostatin Analogues (LA SSAs) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Long-acting Somatostatin Analogues (LA SSAs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Long-acting Somatostatin Analogues (LA SSAs) Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Manufacturers (2021-2026) Table 8. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue of Manufacturers (2021-2026) Table 9. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Long-acting Somatostatin Analogues (LA SSAs) Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Long-acting Somatostatin Analogues (LA SSAs) Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Long-acting Somatostatin Analogues (LA SSAs), Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Long-acting Somatostatin Analogues (LA SSAs), Product Type & Application Table 14. Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Long-acting Somatostatin Analogues (LA SSAs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Chiesi Farmaceutici S.p.A Company Information Table 19. Chiesi Farmaceutici S.p.A Business Overview Table 20. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 22. Chiesi Farmaceutici S.p.A Recent Developments Table 23. Ipsen Company Information Table 24. Ipsen Business Overview Table 25. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 27. Ipsen Recent Developments Table 28. Recordati Rare Diseases Company Information Table 29. Recordati Rare Diseases Business Overview Table 30. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 32. Recordati Rare Diseases Recent Developments Table 33. Novartis Company Information Table 34. Novartis Business Overview Table 35. Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Novartis Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 37. Novartis Recent Developments Table 38. Teva Company Information Table 39. Teva Business Overview Table 40. Teva Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Teva Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 42. Teva Recent Developments Table 43. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2021-2026) & (K Units) Table 45. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Region (2021-2026) Table 46. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2027-2032) & (K Units) Table 47. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Region (2027-2032) Table 48. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region (2021-2026) & (US$ Million) Table 49. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region (2021-2026) Table 50. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region (2027-2032) & (US$ Million) Table 51. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region (2027-2032) Table 52. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 53. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 54. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 55. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2021-2026) & (US$ Million) Table 56. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2027-2032) & (US$ Million) Table 57. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 59. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 60. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2021-2026) & (US$ Million) Table 61. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2027-2032) & (US$ Million) Table 62. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 64. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 65. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2021-2026) & (US$ Million) Table 66. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2027-2032) & (US$ Million) Table 67. South America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. South America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 69. South America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 70. South America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2021-2026) & (US$ Million) Table 71. South America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2027-2032) & (US$ Million) Table 72. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 74. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 75. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2021-2026) & (US$ Million) Table 76. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2027-2032) & (US$ Million) Table 77. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 78. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2027-2032) & (K Units) Table 79. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2021-2026) Table 80. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2027-2032) Table 81. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2026) & (US$ Million) Table 82. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2027-2032) & (US$ Million) Table 83. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2021-2026) Table 84. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2027-2032) Table 85. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2021-2026) & (US$/Unit) Table 86. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2027-2032) & (US$/Unit) Table 87. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 88. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2027-2032) & (K Units) Table 89. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2021-2026) Table 90. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2027-2032) Table 91. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2026) & (US$ Million) Table 92. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2027-2032) & (US$ Million) Table 93. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2021-2026) Table 94. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2027-2032) Table 95. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2021-2026) & (US$/Unit) Table 96. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2027-2032) & (US$/Unit) Table 97. Key Raw Materials Table 98. Raw Materials Key Suppliers Table 99. Long-acting Somatostatin Analogues (LA SSAs) Distributors List Table 100. Long-acting Somatostatin Analogues (LA SSAs) Customers List Table 101. Long-acting Somatostatin Analogues (LA SSAs) Industry Trends Table 102. Long-acting Somatostatin Analogues (LA SSAs) Industry Drivers Table 103. Long-acting Somatostatin Analogues (LA SSAs) Industry Restraints Table 104. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Long-acting Somatostatin Analogues (LA SSAs) Product Image Figure 5. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size (2021-2032) & (US$ Million) Figure 7. Global Long-acting Somatostatin Analogues (LA SSAs) Sales (2021-2032) & (K Units) Figure 8. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price (US$/Unit) & (2021-2032) Figure 9. Injections Product Image Figure 10. Oral Capsules Product Image Figure 11. Neuroendocrine Tumors Product Image Figure 12. Acromegaly Product Image Figure 13. Other Product Image Figure 14. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Long-acting Somatostatin Analogues (LA SSAs), Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Long-acting Somatostatin Analogues (LA SSAs) Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region in 2025 Figure 20. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region in 2025 Figure 21. North America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country in 2025 Figure 22. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2032) Figure 23. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Country (2021-2032) Figure 24. United States Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country in 2025 Figure 28. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2032) Figure 29. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Country (2021-2032) Figure 30. Germany Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country in 2025 Figure 41. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Country (2021-2032) Figure 43. China Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country in 2025 Figure 52. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2032) Figure 53. South America Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Country (2021-2032) Figure 54. Brazil Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country in 2025 Figure 58. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Country (2021-2032) Figure 60. Egypt Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Long-acting Somatostatin Analogues (LA SSAs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2021-2032) Figure 66. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2021-2032) Figure 67. Global Long-acting Somatostatin Analogues (LA SSAs) Price (US$/Unit) by Type (2021-2032) Figure 68. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2021-2032) Figure 69. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2021-2032) Figure 70. Global Long-acting Somatostatin Analogues (LA SSAs) Price (US$/Unit) by Application (2021-2032) Figure 71. Long-acting Somatostatin Analogues (LA SSAs) Value Chain Figure 72. Long-acting Somatostatin Analogues (LA SSAs) Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Long-acting Somatostatin Analogues (LA SSAs) Industry Opportunities and Challenges

Scope & coverage.

Types
  • Injections
  • Oral Capsules
Applications
  • Neuroendocrine Tumors
  • Acromegaly
  • Other
Companies covered
  • Chiesi Farmaceutici S.p.A
  • Ipsen
  • Recordati Rare Diseases
  • Novartis
  • Teva

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size (2021-2032)
  4. 2.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales (2021-2032)
  5. 2.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Market Average Price (2021-2032)
  6. 2.3 Long-acting Somatostatin Analogues (LA SSAs) by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Injections
  9. 2.3.3 Oral Capsules
  10. 2.4 Long-acting Somatostatin Analogues (LA SSAs) by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Neuroendocrine Tumors
  13. 2.4.3 Acromegaly
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Long-acting Somatostatin Analogues (LA SSAs) Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Long-acting Somatostatin Analogues (LA SSAs), Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Long-acting Somatostatin Analogues (LA SSAs), Product Type & Application
  8. 3.8 Global Manufacturers of Long-acting Somatostatin Analogues (LA SSAs), Established Date
  9. 3.9 Global Long-acting Somatostatin Analogues (LA SSAs) Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chiesi Farmaceutici S.p.A
  2. 4.1.1 Chiesi Farmaceutici S.p.A Company Information
  3. 4.1.2 Chiesi Farmaceutici S.p.A Business Overview
  4. 4.1.3 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  6. 4.1.5 Chiesi Farmaceutici S.p.A Recent Developments
  7. 4.2 Ipsen
  8. 4.2.1 Ipsen Company Information
  9. 4.2.2 Ipsen Business Overview
  10. 4.2.3 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  12. 4.2.5 Ipsen Recent Developments
  13. 4.3 Recordati Rare Diseases
  14. 4.3.1 Recordati Rare Diseases Company Information
  15. 4.3.2 Recordati Rare Diseases Business Overview
  16. 4.3.3 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  18. 4.3.5 Recordati Rare Diseases Recent Developments
  19. 4.4 Novartis
  20. 4.4.1 Novartis Company Information
  21. 4.4.2 Novartis Business Overview
  22. 4.4.3 Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  24. 4.4.5 Novartis Recent Developments
  25. 4.5 Teva
  26. 4.5.1 Teva Company Information
  27. 4.5.2 Teva Business Overview
  28. 4.5.3 Teva Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Teva Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  30. 4.5.5 Teva Recent Developments
5 Global Long-acting Somatostatin Analogues (LA SSAs) Market Scenario by Region
  1. 5.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2021-2032
  3. 5.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2021-2026
  4. 5.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2027-2032
  5. 5.3 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region: 2021-2032
  6. 5.3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region: 2021-2026
  7. 5.3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region: 2027-2032
  8. 5.4 North America Long-acting Somatostatin Analogues (LA SSAs) Market Facts & Figures by Country
  9. 5.4.1 North America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2032)
  11. 5.4.3 North America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Long-acting Somatostatin Analogues (LA SSAs) Market Facts & Figures by Country
  16. 5.5.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2032)
  18. 5.5.3 Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Long-acting Somatostatin Analogues (LA SSAs) Market Facts & Figures by Country
  41. 5.7.1 South America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2032)
  43. 5.7.3 South America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2032)
  2. 6.1.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2021-2032)
  4. 6.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2032)
  5. 6.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2032)
  2. 7.1.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2021-2032)
  4. 7.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2032)
  5. 7.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Long-acting Somatostatin Analogues (LA SSAs) Value Chain Analysis
  2. 8.1.1 Long-acting Somatostatin Analogues (LA SSAs) Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Long-acting Somatostatin Analogues (LA SSAs) Production Mode & Process
  5. 8.2 Long-acting Somatostatin Analogues (LA SSAs) Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Long-acting Somatostatin Analogues (LA SSAs) Distributors
  8. 8.2.3 Long-acting Somatostatin Analogues (LA SSAs) Customers
9 Global Long-acting Somatostatin Analogues (LA SSAs) Analyzing Market Dynamics
  1. 9.1 Long-acting Somatostatin Analogues (LA SSAs) Industry Trends
  2. 9.2 Long-acting Somatostatin Analogues (LA SSAs) Industry Drivers
  3. 9.3 Long-acting Somatostatin Analogues (LA SSAs) Industry Opportunities and Challenges
  4. 9.4 Long-acting Somatostatin Analogues (LA SSAs) Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst